449 related articles for article (PubMed ID: 17348829)
1. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
Moreira IS; Fernandes PA; Ramos MJ
Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
Verheul HM; Pinedo HM
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755
[TBL] [Abstract][Full Text] [Related]
6. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and its inhibitors.
Verheul HM; Pinedo HM
Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor as a target for anticancer therapy.
Ferrara N
Oncologist; 2004; 9 Suppl 1():2-10. PubMed ID: 15178810
[TBL] [Abstract][Full Text] [Related]
16. [VEGF-receptor inhibitors for anti-angiogenesis].
Shibuya M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
[TBL] [Abstract][Full Text] [Related]
17. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
Kiselyov A; Balakin KV; Tkachenko SE
Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
[TBL] [Abstract][Full Text] [Related]
18. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Homsi J; Daud AI
Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
Schenone S; Bondavalli F; Botta M
Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
